Stockscreener 앱 받기
7.14
0.97%
-0.07
Neuraxis Inc 주식(NRXS)의 최신 뉴스
Neuraxis, Inc. Files Form 8-K with SEC: Company Details, Address, and Stock Listing on NYSE American - Minichart
NeurAxis Declares Q2 Stock Dividend on Series B - TipRanks
Neuraxis declares stock dividend for Series B preferred, ~80,463 common shares to be issued - TradingView
NRXSNeuraxis Inc Latest SEC Filings - Finviz
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Growth Benchmark - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Index - marketscreener.com
NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Index - marketscreener.com
Price to sales forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to sales forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to EBIT forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Price to book forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Enterprise value to revenue forward of Neuraxis, Inc. – AMEX:NRXS - TradingView
Price to earnings forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
Enterprise value to EBITDA forward of Neuraxis, Inc. – BOATS:NRXS - TradingView
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentProfit Inflection Point - dars.gov.et
NeurAxis, Inc. Actuals & Estimates (AMEX:NRXS) - TradingView
NRXS Forecast — Price Target — Prediction for 2027 - TradingView
Neuraxis Inc (NRXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuraxis Inc (NRXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Neuraxis Inc (NRXS) Institutional Confidence - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Surprises Market, Shares Drop 2.76%Balance Sheet Strength - dars.gov.et
NeurAxis Stockholders Approve Directors and Equity Compensation Plans - The Globe and Mail
Neuraxis elects board members and approves plan amendments at annual meeting - Investing.com
NRXS Q1 2026 Earnings: Smaller-than-Expected Loss Bolsters Investor SentimentShare Repurchase Impact - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Development FocusGuidance Accuracy Score - newsline.com
NRXS Q1 2026 Earnings: EPS Beats Estimates but Stock Declines on Broader ConcernsRetail Earnings Report - dars.gov.et
NRXS Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Tightens LossesEstimate Revision Count - The Legal Advocate
NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionForward EPS Estimate - thelegaladvocate.com
Neuraxis Inc. (NRXS) Slides 2.15% as Key Support Level TestedPCR Divergence - The Legal Advocate
NRXS: Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets - TradingView
NRXS Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceRevenue Warning Signal - The Legal Advocate
Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Surpasses Estimates Amid Operational ProgressGAAP Earnings Report - The Legal Advocate
NRXS: Neuromodulation therapies for GI disorders drive growth with FDA clearance and strong clinical data - TradingView
Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser
Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Slips on Pre‑Revenue Concerns - Newser
NeurAxis Earnings Call Highlights Growth and Hurdles - The Globe and Mail
NeurAxis (NRXS) Gains on Reimbursement Updates and Guideline MomentumShare Dilution Risk - The Legal Advocate
Minot Light Capital Fund Drops 2.7 Percent Amid Sector Rotation - HarianBasis.co
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Insider Monkey
Neuraxis (NRXS) Stock Analysis: -5.84% Loss — Key Levels 2026-05-18Stock Idea Hub - Newser
NeurAxis slides 21%, raises $5M via stock - MSN
The surprise hidden in Neuraxis NRXS last earnings report Q4 2025 Earnings Beat EstimatesCrowd Verified Signals - Newser
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y - Yahoo Finance
NeurAxis revenues up 80% to USD 1.6M in Q1 2026 - Medical Buyer
2.64%
자본화:
|
볼륨(24시간):